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Abstract
Background: The emergence of drug resistance in treated populations and the transmission of drug
resistant strains to newly infected individuals are important public health concerns in the prevention and
control of infectious diseases such as HIV and influenza. Mathematical modelling may help guide the design
of treatment programs and also may help us better understand the potential benefits and limitations of
prevention strategies.
Methods: To explore further the potential synergies between modelling of drug resistance in HIV and in
pandemic influenza, the Public Health Agency of Canada and the Mathematics for Information Technology
and Complex Systems brought together selected scientists and public health experts for a workshop in
Ottawa in January 2007, to discuss the emergence and transmission of HIV antiviral drug resistance, to
report on progress in the use of mathematical models to study the emergence and spread of drug resistant
influenza viral strains, and to recommend future research priorities.
Results: General lectures and round-table discussions were organized around the issues on HIV drug
resistance at the population level, HIV drug resistance in Western Canada, HIV drug resistance at the host
level (with focus on optimal treatment strategies), and drug resistance for pandemic influenza planning.
Conclusion: Some of the issues related to drug resistance in HIV and pandemic influenza can possibly be
addressed using existing mathematical models, with a special focus on linking the existing models to the
data obtained through the Canadian HIV Strain and DR Surveillance Program. Preliminary statistical
analysis of these data carried out at PHAC, together with the general model framework developed by Dr.
Blower and her collaborators, should provide further insights into the mechanisms behind the observed
trends and thus could help with the prediction and analysis of future trends in the aforementioned items.
Remarkable similarity between dynamic, compartmental models for the evolution of wild and drug
resistance strains of both HIV and pandemic influenza may provide sufficient common ground to create
synergies between modellers working in these two areas. One of the key contributions of mathematical
modeling to the control of infectious diseases is the quantification and design of optimal strategies,
combining techniques of operations research with dynamic modeling would enhance the contribution of
mathematical modeling to the prevention and control of infectious diseases.
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Background
The emergence of drug resistance in treated populations
and the transmission of drug resistant strains to newly
infected individuals are important public health concerns
in the prevention and control of infectious diseases such
as HIV and influenza. Mathematical modelling may help
guide the design of HIV treatment programs to minimize
the development and spread of drug resistant strains.
Modelling may also help us achieve a better understand-
ing of the optimal use of antiviral drugs as the first line of
defence against a new strain of influenza and of the poten-
tial benefits and limitations of mitigation strategies using
antiviral drugs during an influenza pandemic.
While acknowledging the fundamental differences in the
evolution of drug resistance between the two diseases, suf-
ficient common ground may be found to create synergies
between modellers working in these two areas. To explore
this further, the Public Health Agency of Canada (PHAC)
and Mathematics for Information Technology and Com-
plex Systems (MITACS, one of the centres of the Network
of Centres of Excellence funded by the Government of
Canada) organized a workshop in Ottawa in January
2007. The workshop brought together selected scientists
and public health experts to discuss the emergence and
transmission of HIV antiviral drug resistance, to report on
progress in the use of mathematical models to study the
emergence and spread of drug resistant influenza viral
strains, and to recommend future research priorities.
In the opening remarks, Dr. Chris Archibald (Surveil-
lance and Risk Assessment Division, PHAC) indicated
that PHAC strongly supports collaboration between mod-
elers and public health policy makers to better understand
the evolution of drug resistant strains and that the
research priority recommendations coming out of the
meeting would be closely examined.
HIV Drug Resistance at the Population Level
Dr. Donald Sutherland (HIV Drug Resistance Strategy,
WHO) spoke about the work of WHO in the area of HIV
drug resistance (DR) and the approach to HIVDR within
the global goal of universal access to anti-retroviral treat-
ment by 2010. He stressed the importance of addressing
the potential problem of drug resistance during the scale-
up of anti-retroviral treatment programs. WHO's program
of HIVDR monitoring follows individuals who are start-
ing HIV treatment for the first time and makes use of a
variety of early warning indicators that may signal a
potential problem with drug supply or treatment compli-
ance, and hence a greater likelihood of the development
of HIV drug resistance. HIVDR transmission surveillance
is done through a threshold survey of a small number of
recently infected persons to assess transmitted HIV drug
resistance; the percentage of persons that show laboratory
evidence of DR is used to decide whether to trigger a set of
specific recommended actions (with 5% being the first
threshold for considering action). Dr. Sutherland con-
cluded by providing a number of useful WHO web links
for HIV treatment and drug resistance information [1-6].
In a lecture entitled "Predicting the Unpredictable: the
Evolution of Drug Resistant HIV Epidemic in Africa", Dr.
Sally Blower (Disease Modeling Group, Semel Institute
for Neuroscience and Human Behavior, UCLA) echoed
the concern that the scale-up of anti-retroviral treatment
could generate an epidemic of drug resistant HIV. She
reviewed her previous modelling work on HIV and anti-
retroviral treatment [7-9] that assesses the dynamics of
wild-type and DR-strains in a population for which a por-
tion of infected individuals receive treatment. For devel-
oped countries where treatment rates are high, her model-
based analysis showed that although treatment increased
the transmission of DR, it significantly decreased HIV
transmission and prevalence and thus could eventually
lead to eradication of the HIV epidemic [7,10,11]. How-
ever, for developing countries where treatment rates are
low (such as for many countries in Africa), there is little
effect on HIVDR transmission and HIV incidence rates are
unlikely to change. WHO is designing a HIVDR transmis-
sion surveillance system in Africa to detect whether trans-
mitted resistance will exceed the threshold of 5%, but Dr.
Blower's analysis for Botswana showed that this threshold
may not be reached for a long time [12-15].
Dr. Sally Blower's lecture also illustrated how mathemati-
cal modelling can be used to help determine the optimal
use of limited resources. She presented recent work [16]
that used operations research techniques to determine the
optimal strategy for allocating anti-retroviral drugs among
health care facilities to ensure that each individual
infected with HIV has an equal chance of receiving treat-
ment.
HIV Drug Resistance in Western Canada
Dr. Gayatri Jayaraman (HIV Drug Resistance and Field
Surveillance Section, PHAC) introduced the Canadian
HIV Strain and DR Surveillance Program. She described
the methods used to collect samples from individuals
newly diagnosed with HIV and to analyze pol  gene
sequences to determine drug resistance mutations accord-
ing to the International AIDS Society-USA list (2005). She
stressed the uniqueness of this surveillance program since
it gathers data at the population level rather than from a
limited number of clinical sites. Dr. Ping Yan (Modelling
& Projection Section, PHAC) then presented his explora-
tory analysis of trends in transmitted drug resistance in
western Canada, and Dr. Shenghai Zhang (Modelling &
Projection Section, PHAC) discussed further stratification
of the population and its impact on the trend analysis.BMC Public Health 2007, 7:300 http://www.biomedcentral.com/1471-2458/7/300
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In summary, this work modeled trends in the prevalence
of transmitted drug resistance using data collected from
this surveillance program for the four provinces of western
Canada between 1998 and 2004. Generalized linear mod-
els were fit to the binary data to examine trends in drug
resistance for three drug classes: nucleoside reverse tran-
scriptase inhibitors (NRTIs), non-nucleoside reverse tran-
scriptase inhibitors (NNRTIs), and protease inhibitors
(PIs). The results showed that while the overall prevalence
of transmitted drug resistance has remained constant over
time, there were significant differences according to drug
class: a decrease in the prevalence of transmitted NRTI
resistance, an increase in the prevalence of transmitted
NNRTI resistance, and little change in the prevalence of
transmitted PI resistance. In addition, there were distinct
differences between provinces in these trends. Possible
reasons for these differences over time and between prov-
inces include changes in drug prescribing patterns and in
risk behaviours. In conclusion, the results highlight the
need for continued national surveillance of transmitted
drug resistance to fully understand inter-regional differ-
ences and the course of the HIV epidemic in Canada [17].
HIV Drug Resistance at the Host Level: Optimal 
Treatment Strategies
Four lectures dealt with HIV drug resistance and optimal
treatment strategies.
Dr. John Mittler (Department of Microbiology, Univer-
sity of Washington) described two kinds of regimen-spar-
ing treatment strategies: structured treatment
interruptions and induction-maintenance therapies. He
then presented his model-based analysis to help deter-
mine the optimal length for the induction phase, ways to
improve the success of induction-maintenance therapy,
and which drugs should be included in the induction and
maintenance regimens [18,19].
Dr. Robert Smith? (Departments of Mathematics and of
Epidemiology, University of Ottawa) emphasized that
mathematical models for HIV treatment should explicitly
account for the mechanics and temporal aspects of drug
dosing. His analysis suggested that the use of PIs alone
may lead to treatment failure, whereas RTIs would lead to
treatment success, whether or not they were combined
with PIs. He also presented his recent work which shows
that to minimize drug resistance, RTI therapy should
remain outside a certain (predictable) parameter region
[20,21].
In his lecture entitled "Emergence and Impact of HIV CTL-
Escape Mutants on Progression to AIDS", Dr. Beni Sahai
(Cadham Provincial Laboratory, Manitoba) presented
several theories for the loss of effectiveness of the anti-HIV
immune response, and concluded that anti-HIV cytotoxic
T-lymphocytes (CTLs) play an essential role in preventing
progression to AIDS and that drug-resistant HIV strains do
not cause a surge of viremia or accelerate progression to
AIDS in the presence of multivalent anti-HIV CTLs.
Dr. Jane Heffernan (Department of Mathematics and Sta-
tistics, York University) noted that viral load and CD4 T-
cell counts in patients infected with HIV are commonly
used to guide clinical decisions regarding drug therapy or
to assess therapeutic outcomes in clinical trials. However,
random fluctuations in CD4 T-cell count and viral load,
due solely to the stochastic nature of HIV infection, can
obscure clinically significant change. She reported her
work [22-24] that employed a Monte Carlo simulation to
investigate the contributing factors in the expected varia-
bility in CD4 T-cell count and viral load. It was found that,
by considering correlations between viral load measure-
ments (in the absence or presence of drug therapy) taken
days or weeks apart, the variability predicted by the Monte
Carlo simulation may reconcile the wide range of variabil-
ity in viral load observed in clinical studies. Dr. Heffernan
discussed how the Monte Carlo simulation can be
extended to investigate the effects of drug resistance, and
noted that the extended model can estimate the probabil-
ity that a drug resistant mutant will emerge before and
during therapy, the speed at which the drug resistant
mutant will dominate once it has emerged, and the prob-
ability that drug therapy will clear the wild type and
mutant viral strains in a small volume of plasma. The sim-
ulation model can also be used to investigate the effects of
imperfect treatment adherence on the emergence of drug
resistance and to quantify the role of the latently-infected
cell pool in harboring drug resistant virus.
Drug Resistance for Pandemic Influenza Planning
Influenza pandemics have historically been devastating to
human populations. Considering the extent of morbidity
and mortality caused by previous pandemics and the
growing threat of an imminent human outbreak of the
avian influenza strain H5N1, identification of effective
mitigation strategies is a major global public health prior-
ity. It has been recognized that pharmaceutical measures
(vaccines, antiviral drugs) would have the greatest impact
in containing a pandemic. However, given the significant
challenges involved in the development of an effective
vaccine against a newly emerging pandemic strain, it is
likely that antiviral drugs will be the sole pharmaceutical
defense. Since a critical limitation to their application is
the emergence of highly transmissible resistant viral
mutants, it is paramount to evaluate the use of these drugs
for both treatment and prophylaxis. To do this, mathe-
matical models need to be developed that not only incor-
porate the population phenomenon of disease
transmission, but also integrate viral evolution and dis-
ease dynamics at the individual level.BMC Public Health 2007, 7:300 http://www.biomedcentral.com/1471-2458/7/300
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Dr. Seyed Moghadas (Institute for Biodiagnostics,
National Research Council of Canada) described a model
to evaluate the potential impact of an antiviral drug strat-
egy on the emergence of drug-resistance and containment
of an influenza pandemic [25]. The model-based simula-
tions reveal that elimination of the wild-type strain
depends on the timely application of drugs for treatment
of index cases and on the level of population coverage by
treatment, and suggest that a single strategy of antiviral
treatment will be successful only if the reproductive
number of the wild-type strain is below 1.9. The results
also showed that the early application of antiviral drugs is
crucial to contain a pandemic, and caution is required to
prevent the emergence of drug-resistant viral mutants
since the evolution of host-pathogen systems occurs on a
short time scale. Resistant strains with sufficiently small
reproductive numbers are soon out-competed, and effec-
tive treatment may therefore result in disease elimination.
However, it is possible that a resistant strain undergoes
further mutations that result in increased transmission fit-
ness. Examination of the past three pandemics suggests
that an outbreak of resistant virus is likely to occur if the
relative transmission fitness of the resistant virus (relative
to wild type) is above 0.4. The results also indicate that for
wild-type viruses with high reproductive numbers, the
control of a pandemic with antiviral treatment requires a
sufficiently low transmission fitness of resistant virus to
rule out the occurrence of an outbreak of resistant virus.
The issue of DR in relation to the use of antivirals for
prophylaxis was also discussed briefly, but this topic
clearly requires further study.
Dr. Murray Alexander (Institute for Biodiagnostics,
National Research Council of Canada) compared deter-
ministic models with individual-based network models
[26-29] and stressed the importance of developing some-
thing between these two extremes due to the uncertainty
of parameter identification and the dependence of current
pandemic models on social network structure.
Dr. John Glasser (Centers for Disease Control and Pre-
vention, USA) spoke about the evaluation of alternative
vaccination and treatment strategies. He presented a
standard compartmental model in which infection rates
reflected different social activities and networking by age-
group [30]. The impact on mortality among the elderly of
vaccinating school children exceeds that of vaccinating the
older adults themselves, and the impact on mortality
among infants was even greater. He noted that in a pan-
demic, anti-viral medications would be scarce and target-
ing their use could help ensure their efficient use and also
mitigate the evolution of drug resistance.
In a discussion facilitated by Drs. Fred Brauer (Depart-
ment of Mathematics, University of British Columbia)
and Zhilan Feng (department of Mathematics, Purdue
University), Dr. Theresa Tam (Immunization and Respi-
ratory Infections Division, PHAC) suggested that pan-
demic influenza plans should incorporate other non-
medical measures (such as social distancing) and she
encouraged further work that examines the drug resist-
ance issue for scenarios involving prophylaxis as well as
treatment.
Round-table Discussions: Next Steps
The workshop ended with a group discussion on next
steps coordinated by Dr. Jianhong Wu (Department of
Mathematics and Statistics and Center for Disease Mode-
ling, York University and MITACS). He first invited Dr.
Jayaraman to comment on the HIV issues that should be
addressed through modeling and Dr. Jayaraman listed
some of the areas where she and her colleagues at PHAC
thought input from modelers would be most useful:
1. To predict the incidence and prevalence of transmitted (and
acquired) drug resistance;
2. To model the contribution of transmitted DR to overall DR
HIV prevalence;
3. To model the contribution of transmitted DR to annual HIV
incidence;
4. To model which factors contribute the most to transmitted
(and acquired) DR and what factors that can minimize the
transmission of DR;
5. To model the level of increased risk behaviour that would off-
set the expected decrease in HIV incidence resulting from wide-
spread anti-retroviral therapy use.
The general discussion suggested that some of these issues
can possibly be addressed using existing mathematical
models, with a special focus on linking the existing mod-
els to the data obtained through the Canadian HIV Strain
and DR Surveillance Program. Participants noted that the
preliminary statistical analysis of these data led by Dr. Yan
has already provided some solutions to items #1–4 in
terms of historical data. This, together with the general
model framework discussed in Dr. Blower's lecture,
should provide further insights into the mechanisms
behind the observed trends and thus could help with the
prediction and analysis of future trends in the aforemen-
tioned items. Participants also noted the remarkable sim-
ilarity between dynamic, compartmental models for the
evolution of wild and drug resistance strains of both HIV
and pandemic influenza, and so the above remarks also
apply to the drug resistance issue for pandemic influenza.
It was suggested that proposals should be prepared to
apply for funding to develop new models and take advan-BMC Public Health 2007, 7:300 http://www.biomedcentral.com/1471-2458/7/300
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tage of the large amount of high quality surveillance data
available at PHAC.
The participants felt the urgent need of high quality clini-
cal data for the study of drug resistance and it was believed
that future collaboration between modelers and public
health policy makers would benefit very much from a cen-
tralized clinical data base. Therefore, it was recommended
that such a data base should be developed as soon as pos-
sible.
Finally, participants observed that one of the key contri-
butions of mathematical modeling to the control of infec-
tious diseases is the quantification and design of optimal
strategies. This was demonstrated in all the lectures of the
workshop and the proposed priority item #5 further rein-
forced this observation. Combining techniques of opera-
tions research with dynamic modeling would enhance the
contribution of mathematical modeling to the prevention
and control of infectious diseases.
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